Diamyd Medical's Phase II study in cancer pain fully recruited

May 2012
Biomedical Market Newsletter;5/25/2012, Vol. 21, p1
The article presents information on the Diamyd Medical AB which has recruited the last patient for the treatment of cancer pain with the drug candidate NP2 Enkephalin. It informs that this clinical trial is the first placebo-controlled clinical trial of a drug candidate. As per Peter Zerhouni, chief executive officer (CEO) of Diamyd Medical, Phase II study is now fully enrolled.


Related Articles

  • Diamyd Medical: Diamyd Replaces CEO.  // Biomedical Market Newsletter;5/28/2011, p693 

    The article announces the appointment of Peter Zerhouni as acting president/chief executive officer (CEO) of Diamyd Medical AB. It states that Elisabeth Lindler resigned from her position as president/CEO of the company due to disagreement with the board which concerns important matters. It...

  • Peter Zerhouni has been appointed Executive VP of Diamyd Medical AB.  // Biomedical Market Newsletter;5/7/2011, p160 

    The article announces the appointment of Peter Zerhouni as executive vice president of Diamyd Medical AB.

  • Diamyd Medical: Diamyd Appoints Peter Zerhouni as President.  // Biomedical Market Newsletter;7/5/2011, p11 

    The article announces the appointment of Peter Zerhouni as president of Diamyd Medical AB.

  • Diamyd Medical Reports Results from Phase II Study in Cancer Pain.  // Biomedical Market Newsletter;7/7/2012, Vol. 21, p1 

    The article informs that the drug NP2 Enkephalin developed by Diamyd Medical AB did not meet its primary objective of reducing pain in cancer patients. NP2 Enkephalin is based on the Medical's patented Nerve Targeting Drug Delivery System (NTDDS) platform and delivers the natural painkilling...

  • Diamyd Medical: Diamyd Reports Initial Results from European Phase III Trial in Patients Newly Diagnosed with Type 1 Diabetes.  // Biomedical Market Newsletter;5/15/2011, p469 

    The article discusses the results obtained by Diamyd Medical AB from its European Phase III trial with Diamyd(r) antigen-based therapy. It states that the therapy did not reach the primary efficacy level of maintaining beta cell function after 15 months in patients with type 1 diabetes. It says...

  • Clinic Roundup.  // BioWorld Today;2/11/2011, Vol. 22 Issue 29, p2 

    This section offers news briefs on drug trials. A Phase II trial is being conducted by Diamyd Medical AB for its NP2 Enkephalin drug for the reduction of cancer pain. Enrollment in a Phase I trial of therapeutic caner vaccine DPX-0907 has been completed by Immunovaccine Inc. A Phase II trial of...

  • Diamyd Medical: Financial Statement 10/11.  // Biomedical Market Newsletter;10/17/2011, Vol. 21, p438 

    The article provides the financial statement of Diamyd Medical AB from June 1, 2011 to August 31, 2011. It mentions its acquisition of rights and control of its Diamyd diabetes therapy following the terminated collaboration agreement with Ortho-McNeil-Janssen Pharmaceuticals Inc. (OMJPI). It...

  • Diamyd Completes Recruitment In Gene Therapy Pain Trial. Sheridan, Cormac // BioWorld International;5/23/2012, p2 

    The article reports on the six percent increase in the value of Diamyd Medical AB stocks after news that it completed recruitment in a Phase II trial of NP2 Enkephalin, its gene therapy treatment for chronic cancer pain. Study results are expected to have an impact on the company's future after...

  • Diamyd Medical: Quarterly Report III 10/11.  // Biomedical Market Newsletter;7/5/2011, p114 

    The article focuses on the quarterly report of Diamyd Medical AB for fiscal year 2010 to 2011. It mentions that in third quarter ranging from March 1, 2011 to May 31, 2011, the group net sales were MSEK 19.5 while profit before tax was MSEK -43.6. It states that during the reporting period, the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics